Claims
- 1. A method for treating neuropathic pain in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of a composition that decreases the current mediated by an HCN pacemaker channel in a sensory cell of the subject.
- 2. The method of claim 1, wherein said neuropathic pain is selected from the group consisting of: carpal tunnel syndrome, central pain, complex regional pain syndrome (CRPS), diabetic neuropathy, opioid resistant pain, phantom limb pain, postmastectomy pain, thalamic syndrome (anesthesia dolorosa), lumbar radiculopathy; cancer related neuropathy, herpetic neuralgia, HIV related neuropathy, multiple sclerosis, and pain caused by immunologic mechanisms, multiple neurotransmitter system dysfunction, nervous system focal ischemia, and neurotoxicity.
- 3. The method of claim 1, wherein said composition decreases the expression of an HCN protein subunit in a sensory cell of the subject.
- 4. The method of claim 1, wherein said composition decreases the probability that the HCN pacemaker channel is open to ion flux.
- 5. The method of claim 1, wherein said composition is an inhibitor of a HCN1 or HCN3 channel.
- 6. The method of claim 1, wherein said composition is selected from ZD7288, ZM-227189, Zatebradine, DK-AH268, alinidine, and ivabradine.
- 7. The method of claim 1 wherein the composition is administered with at least one other analgesic.
- 8. The method of claim 7 wherein said other analgesic is selected from morphine or another opiate receptor agonists; nalbuphine or another mixed opioid agonist/antagonists; tramadol; baclofen; clonidine or another alpha-2 adrenoreceptor agonists; amitriptyline or another tricyclic antidepressants; gabapentin or pregabalin, carbamazepine, phenytoin, lamotrigine, or another anticonvulsants; and/or lidocaine, tocainide, or another local anesthetics/antiarrhythmics.
- 9. A method of identifying a compound useful for treating neuropathic pain, comprising the steps of:
(a) contacting a test compound with an HCN pacemaker protein; and (b) determining the ability of the compound to decrease the current density of an HCN pacemaker channel.
- 10. The method of claim 9 further comprising the step of testing the compound in a neuropathic pain animal model.
- 11. The method of claim 9, wherein the protein comprises an HCN1 or HCN3 pacemaker subunit.
- 12. The method of claim 9 wherein said HCN pacemaker protein is substantially purified.
- 13. The method of claim 9 wherein said HCN pacemaker protein is associated with a membrane.
- 14. The method of claim 9 wherein said HCN pacemaker protein is expressed from a host cell.
- 15. A method of identifying a compound useful for treating neuropathic pain, comprising the steps of:
(a) combining a test compound, a measurably labeled ligand for an HCN pacemaker protein, and an HCN pacemaker protein; and (b) measuring binding of the compound to the HCN pacemaker protein by a reduction in the amount of labeled ligand binding to the HCN pacemaker protein.
- 16. The method of claim 15 additionally comprising the step of testing the compound in an animal model for neuropathic pain.
- 17. The method of claim 15 wherein said HCN pacemaker protein is substantially purified.
- 18. The method of claim 15 wherein said HCN pacemaker protein is associated with a membrane.
- 19. The method of claim 15 wherein said HCN pacemaker protein is expressed in a host cell.
- 20. The method of claim 15 wherein said protein is an HCN1 or HCN3 pacemaker protein.
- 21. Use of a composition capable of decreasing the current mediated by an HCN pacemaker channel in a sensory cell of the subject having neuropathic pain.
FIELD OF THE INVENTION
[0001] This Patent application claims priority from U.S. Provisional Patent Application No. 60/297,108 filed Jun. 8, 2001 entitled “DRG 1H and HCN Association with Neuropathic Pain”, from U.S. Provisional Patent Application No. 60/347,945 filed Nov. 7, 2001 and entitled “Markedly Increased 1H and Regulation of HCN accompany Neuropathic Pain in the Rat”, and from U.S. Provisional Patent Application No. 60/373,012 filed Apr. 16, 2002 and entitled “Treating Pain By Targetting Hyperpolarization-Activated, Cyclic Nucleotide-Gated Channels”, the contents of which are hereby incorporated herein in their entirety.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60297108 |
Jun 2001 |
US |
|
60347945 |
Nov 2001 |
US |
|
60373012 |
Apr 2002 |
US |